Format

Send to

Choose Destination
See comment in PubMed Commons below
Eur J Immunol. 2009 Jan;39(1):36-46. doi: 10.1002/eji.200838620.

Safety and efficacy of neonatal vaccination.

Author information

  • 1Department of Medicine, Division of Infectious Diseases, Children's Hospital Boston, Boston, MA 02115, USA.

Abstract

Newborns have an immature immune system that renders them at high risk for infection while simultaneously reducing responses to most vaccines, thereby posing challenges in protecting this vulnerable population. Nevertheless, certain vaccines, such as BCG and Hepatitis B vaccine, do demonstrate safety and some efficacy at birth, providing proof of principal that certain antigen-adjuvant combinations are able to elicit protective neonatal responses. Moreover, birth is a major point of healthcare contact globally meaning that effective neonatal vaccines achieve high population penetration. Given the potentially significant benefit of vaccinating at birth, availability of a broader range of more effective neonatal vaccines is an unmet medical need and a public health priority. This review focuses on safety and efficacy of neonatal vaccination in humans as well as recent research employing novel approaches to enhance the efficacy of neonatal vaccination.

PMID:
19089811
PMCID:
PMC2739303
DOI:
10.1002/eji.200838620
[PubMed - indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wiley Icon for PubMed Central
    Loading ...
    Support Center